Treatment with antiviral entry inhibitor bulevirtide shown to achieve significant response in chronic hepatitis delta virus after 24 weeks

Interim data from Phase III study (MYR301) show that that after 24 weeks, the proportion of people achieving the combined virological and biochemical response was 36.7% with bulevirtide 2mg, 28% with 10mg and 0% in those under observation (p<0.001 for both doses v no treatment).

Source:

Biospace Inc.